Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T14:42:14.615Z.
Calculation as of: 2026-10-06T14:42:14.615Z.
Quote observation: 2026-10-06T14:40:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 521b0ab3da901f2a49dafbbedcb3688a082548b97bbb2cd5efdb729e6989e7c5
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
TuHURA Biosciences, Inc.
Market Cap
$119.72M
EV/FCF Ratio
N/A
| NAME | MARKET CAP | EV/FCF RATIO |
|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $119.72M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $121.22M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $122.96M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $117.21M | N/A |
| Cibus, Inc. (CBUS)vs › | $123.66M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.11M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.54M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $125.44M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $114.62M | N/A |
| Genelux Corporation (GNLX)vs › | $114.34M | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
